OIPE JC106
MAR 0 4 2004
PATENT & TRADEMARK OFFICE


PARALLEL BglII REPRESENTATIONS
DECREASED Cy5–INCREASED Cy5
6 4 2 2 4 6
Cy3 CHANNEL INTENSITY
3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4 2 3 4 5 6 7

FIG. 8A


SELF TO SELF
DECREASED Cy5-INCREASED Cy5
6
4
2
2
4
6
Cy3 CHANNEL INTENSITY
3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4
3 4 5 6 7

FIG. 8B


TUMOR vs. NORMAL
DECREASED Cy5–INCREASED Cy5
6 4 2 2 4 6
NORMAL CHANNEL INTENSITY
3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4 2 3 4 5 6 7

FIG. 8C


COMPARISON OF TWO EXPERIMENTS
SKBR-3 vs MDA-MB-415
RATIOS, EXP 2
RATIOS, EXP 1
$10^{-1.0}$
$10^{0.0}$
$10^{-1.0}$
$10^{0.0}$
2 3 4 5 6 7 8
2 3 4 5 6 7 8

FIG.9


COMPARISON OF ARRAY AND BLOT HYBRIDIZATION
BLOT HYBRIDIZATION RATIO
ARRAY HYBRIDIZATION RATIO
0
1
2
3
4
5
6

FIG. 11


BglI: SKBR-3 vs MDA-MB-415
COPY NUMBER MDA-MB-415-COPY NUMBER SKBR-3
MDA-MB-415 CHANNEL INTENSITY
7 6 10^2 2 3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4 2 3 4 5 6 7 8 9
6 4 2 2 4 6

FIG. 12A


DpnII: SKBR-3 vs MDA-MB-415
COPY NUMBER MDA-MB-415-COPY NUMBER SKBR-3
6
4
2
2
4
6
2 3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4 2 3 4 5 6 7 8 9
MDA-MB-415 CHANNEL INTENSITY

FIG. 12B


DpnII: SKBR-3 vs MDA-MB-415
COPY NUMBER MDA-MB-415-COPY NUMBER SKBR-3
1.8
1.4
1.4
1.8
MDA-MB-415 CHANNEL INTENSITY
10^2 2 3 4 5 6 7 8 10^3 2 3 4 5 6 7 8 10^4 2 3 4 5 6 7 8 9

FIG. 12C